WuXi XDC Cayman (FRA:L74) Interest Expense : €-0.1 Mil (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. WuXi XDC Cayman's interest expense for the three months ended in Jun. 2023 was € -0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. WuXi XDC Cayman's Operating Income for the three months ended in Jun. 2023 was € 11.4 Mil. WuXi XDC Cayman's Interest Expense for the three months ended in Jun. 2023 was € -0.0 Mil. WuXi XDC Cayman's Interest Coverage for the quarter that ended in Jun. 2023 was 634.00. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

WuXi XDC Cayman Interest Expense Historical Data

The historical data trend for WuXi XDC Cayman's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Interest Expense Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.07

-0.40

-0.10

WuXi XDC Cayman Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial			-0.16	-	-0.06	-0.02	-

WuXi XDC Cayman Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.1 Mil.

WuXi XDC Cayman (FRA:L74) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

WuXi XDC Cayman's Interest Expense for the three months ended in Jun. 2023 was €-0.0 Mil. Its Operating Income for the three months ended in Jun. 2023 was €11.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2023 was €0.3 Mil.

WuXi XDC Cayman's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2023 )	/	Interest Expense (Q: Jun. 2023 )
	=	-1	*	11.412	/	-0.018
	=	634.00

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. WuXi XDC Cayman Inc has enough cash to cover all of its debt. Its financial situation is stable.

WuXi XDC Cayman (FRA:L74) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (FRA:L74) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

02268:Hong Kong

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (FRA:L74) Headlines

No Headlines